Drug tolerability data from clinical trials.

Details regarding erlotinib and evofosfamide dosing schedules tested in clinical trials and how this data informs the construction of the toxicity constraint curve for each drug. The dose administered is shown in the first column, and the corresponding dosing schedule is shown in the second column. The third column shows whether or not this particular dosing schedule was tolerated in the clinical trial. The fourth column shows the ordered pair this dosing schedule corresponds to, and the last column shows the location of this point relative to the toxicity constraint curve. We assume that any point corresponding to a maximum tolerated dosing schedule tested in a clinical trial can either lie on or below the toxicity constraint curve to account for the possibility that a higher dose (which was not tested in the trial) is tolerated.